Advertisement

International Journal of Clinical Pharmacy

, Volume 33, Issue 2, pp 191–199 | Cite as

Induction-related cost of patients with acute myeloid leukaemia in France

  • Virginie Nerich
  • Bruno Lioure
  • Maryline Rave
  • Christian Recher
  • Arnaud Pigneux
  • Brigitte Witz
  • Martine Escoffre-Barbe
  • Marie-Pierre Moles
  • Eric Jourdan
  • Jean Yves Cahn
  • Marie-Christine Woronoff-LemsiEmail author
Research Article

Abstract

Objective The economic profile of acute myeloid leukaemia (AML) is badly known. The few studies published on this disease are now relatively old and include small numbers of patients. The purpose of this retrospective study was to evaluate the induction-related cost of 500 patients included in the AML 2001 trial, and to determine the explanatory factors of cost. Setting “Induction” patient’s hospital stay from admission for “induction” to discharge after induction. Method The study was performed from the French Public Health insurance perspective, restrictive to hospital institution costs. The average management of a hospital stay for “induction” was evaluated according to the analytical accounting of Besançon University Teaching Hospital and the French public Diagnosis-Related Group database. Multiple linear regression was used to search for explanatory factors. Main outcome measure Only direct medical costs were included: treatment and hospitalisation. Results Mean induction-related direct medical cost was estimated at €41,852 ± 6,037, with a mean length of hospital stay estimated at 36.2 ± 10.7 days. After adjustment for age, sex and performance status, only two explanatory factors were found: an additional induction course and salvage course increased induction-related cost by 38% (±4) and 15% (±1) respectively, in comparison to one induction. These explanatory factors were associated with a significant increase in the mean length of hospital stay: 45.8 ± 11.6 days for 2 inductions and 38.5 ± 15.5 if the patient had a salvage course, in comparison to 32.9 ± 7.7 for one induction (P < 10−4). This result is robust and was confirmed by sensitivity analysis. Conclusion Consideration of economic constraints in health care is now a reality. Only the control of length of hospital stay may lead to a decrease in induction-related cost for patients with AML.

Keywords

Acute myeloid leukaemia Cost Economic burden Explanatory factors France Induction 

Notes

Acknowledgments

We would like thank all centres contributing to this study and transmitting data from the French PMSI: Toulouse, Bordeaux, Nancy, Rennes, Strasbourg, Angers, Clermont-Ferrand, Besançon, Limoges, Saint Etienne, Nice, Tours, Dijon, Avignon, Colmar et Nîmes. We also thank Ms Pamela Albert for English assistance in the correction of the manuscript.

Conflicts of interest

The authors declare no conflict of interest with regard to this publication.

References

  1. 1.
    Bishop Y, Fienberg S, Holland P. Discrete multivariate analysis: theory and practice. Cambridge, MA: The MIT Press; 1975. p. 492–7.Google Scholar
  2. 2.
    Borella L, Peuvrel P, Sauvage M, Maraninchi D, Philip T. A study based on national DRG data to evaluate work load and practice relating to cancer patients in not-for-profit hospitals. Rev Epidemiol Sante Publique. 2000;48(1):53–70.PubMedGoogle Scholar
  3. 3.
    Chaumard N, Fagnoni P, Nerich V, Limat S, Dussaucy A, Chalopin JM, et al. Hospital costs of renal transplant management. Transplant Proc. 2008;40(10):3440–4.PubMedCrossRefGoogle Scholar
  4. 4.
    Clavio M, Quintino S, Masoudi B, Carrara S, Cerri R, Pierri I, et al. Cost of de novo acute myeloid leukemia induction therapy in adults: analysis of EORTC-GIMEMA AML10 and FLANG regimens. J Exp Clin Cancer Res. 2001;20(2):165–73.PubMedGoogle Scholar
  5. 5.
    Fagnoni P, Limat S, Hintzy-Fein E, Martin F, Deconinck E, Cahn JY, et al. Cost of hospital-based management of acute myeloid leukemia: from analytical to procedure-based tarification. Bull Cancer. 2006;93(8):813–9.PubMedGoogle Scholar
  6. 6.
    Kasteng F, Sobocki P, Svedman C, Lundkvist J. Economic evaluations of leukemia: a review of the literature. Int J Technol Assess Health Care. 2007;23(1):43–53.PubMedCrossRefGoogle Scholar
  7. 7.
    Lioure B, Pigneux A, Recher C, Witz F, Lamy T, Fegueux N et al. No Benefit of Adding High-Dose Melphalan (HDM) Suppported by Autologous Stem Cell Transplantation (SCT) over Treatment with Conventional Induction, HD ARAC Consolidation, and Auto SCT (Busulfan + HDM) for Acute Myelogenous Leukemia (AML) under 60: First Results of the Randomized AML 2001 Trial. Blood. 2006; 108(11):abstract 608.Google Scholar
  8. 8.
    Lobo PJ, Powles RL, Hanrahan A, Reynold DK. Acute myeloblastic leukaemia-a model for assessing value for money for new treatment programmes. Br Med J. 1991;302(6772):323–6.CrossRefGoogle Scholar
  9. 9.
    Manning W, Mullahy J. Estimating log models: to transform or not to transform? J Health Econ. 2001;20(4):461–94.PubMedCrossRefGoogle Scholar
  10. 10.
    Marie JP, Bisserbe S, Bouaziz C, Wdowick T, Zittoun R. A program for medical use of information systems. Validity of calculation of direct costs for the initial treatment of acute myeloblastic leukemia. Presse Med. 1992;21(29):1364–8.Google Scholar
  11. 11.
    Marie JP, Wdowik T, Bisserbe S, Zittoun R. Cost of complete remission induction in acute myeloblastic leukemia: evaluation of the cost-effectiveness of a new drug. Leukemia. 1992;6(7):720–2.PubMedGoogle Scholar
  12. 12.
    Pashko S, Jacobs J, Santorsa J. The cost-effectiveness of idarubicin/cytosine arabinoside versus daunorubicin/cytosine arabinoside in the treatment of adults with acute myeloid leukemia. Clin Ther. 1991;13(3):353–60.PubMedGoogle Scholar
  13. 13.
    Redaelli A, Botteman MF, Stephens JM, Brandt S, Pashos CL. Economic burden of acute myeloid leukemia: a literature review. Cancer Treat Rev. 2004;30(3):237–47.PubMedCrossRefGoogle Scholar
  14. 14.
    Stalfelt AM, Brodin H. Costs over time in conventional treatment of acute myeloid leukaemia. A study exploring changes in treatment strategies over two decades. J Intern Med. 1994;236(4):401–9.Google Scholar
  15. 15.
    Tennvall GR, Persson U, Nilsson B. The economic costs of acute myeloid leukemia in Sweden. Int J Technol Assess Health Care. 1994;10(4):683–94.PubMedCrossRefGoogle Scholar
  16. 16.
    Uyl-de Groot CA, Gelderblom-den Hartog J, Huijgens PC, Willemze R, Van Ineveld BM. Costs of diagnosis, treatment, and follow up of patients with acute myeloid leukemia in the netherlands. J Hematother Stem Cell Res. 2001;10(1):187–92.PubMedCrossRefGoogle Scholar
  17. 17.
    Uyl-de Groot Ca, Lowenberg B, Vellenga E, Suciu S, Willemze R, Rutten FF. Cost-effectiveness and quality-of-life assessment of GM-CSF as an adjunct to intensive remission induction chemotherapy in elderly patients with acute myeloid leukemia. Br J Haematol. 1998;100(4):629–36.Google Scholar
  18. 18.
    Uyl-de Groot CA, Okhuijsen SY, Hagenbeel A, Huijgens PC, van Imhoff GW, Löwenberg B, et al. Costs of introducing autologous BMT in the treatment of lymphoma and acute leukaemia in The Netherlands. Bone Marrow Transplant. 1995;15(4):605–10.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2011

Authors and Affiliations

  • Virginie Nerich
    • 1
    • 2
  • Bruno Lioure
    • 3
  • Maryline Rave
    • 1
  • Christian Recher
    • 4
  • Arnaud Pigneux
    • 5
  • Brigitte Witz
    • 6
  • Martine Escoffre-Barbe
    • 7
  • Marie-Pierre Moles
    • 8
  • Eric Jourdan
    • 9
  • Jean Yves Cahn
    • 10
  • Marie-Christine Woronoff-Lemsi
    • 1
    • 2
    • 11
    Email author
  1. 1.Department of PharmacyUniversity Hospital of BesançonBesançonFrance
  2. 2.EA4267–UFR-133School of Medicine and PharmacyBesançonFrance
  3. 3.Department of HematologyUniversity Teaching HospitalStrasbourgFrance
  4. 4.Department of HematologyUniversity Teaching HospitalToulouseFrance
  5. 5.Department of HematologyUniversity Teaching HospitalBordeauxFrance
  6. 6.Department of HematologyUniversity Teaching HospitalNancyFrance
  7. 7.Department of HematologyUniversity Teaching HospitalRennesFrance
  8. 8.Department of HematologyUniversity Teaching HospitalAngersFrance
  9. 9.Department of HematologyUniversity Teaching HospitalNîmesFrance
  10. 10.Department of HematologyUniversity Teaching HospitalGrenobleFrance
  11. 11.Centre Hospitalier Universitaire, Pôle PharmaceutiqueBesancon CedexFrance

Personalised recommendations